About Contact Us Careers
Sign In

Antibody Validation Market - Top Companies and Manufacturers

  • Report ID: 5010
  • Published Date: Jun 13, 2023
  • Report Format: PDF, PPT

Companies Dominating the Antibody Validation Landscape

top-features-companies
    • General Electric
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Merck KGaA
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann La-Roche Ltd
    • Rockland Immunochemicals Inc.
    • Johnson & Johnson private Limited
    • Agilent Technologies Inc.
    • Eli Lily and Company
    • Becton, Dickinson and Company 
    • Danaher
Browse Key Market Insights with Data Illustration:

In the News

  • Leading science and technology company Merck KGaA revealed that its Life Science division's ZooMAb recombinant antibody platform has been granted an Accountability, Consistency, and Transparency (ACT) label by My Green Lab, a non-profit devoted to fostering a culture of sustainability in science.
  • Thermo Fisher Scientific Inc. has released two new SARS-CoV-2 antibody tests: The Thermo Scientific OmniPATH COVID-19 Total Antibody ELISA test and the Thermo Scientific EliA SARS-CoV-2-Sp1 IgG test. Thermo Fisher Scientific Inc. is the world leader in providing science services.

Author Credits:  Radhika Pawar


  • Report ID: 5010
  • Published Date: Jun 13, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are the growing prevalence of autoimmune disease, the rise in the need for early detection of cancer, and the advancement of strategies.

The market size of antibody validation is anticipated to attain a CAGR of ~14% over the forecast period, i.e., 2023 – 2035.

The major players in the market are General Electric, Merck KGaA, Thermo Fisher Scientific Inc., F. Hoffmann La-Roche Ltd, and more.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product type, disease indication, end user and by region.

The monoclonal antibodies segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Require high investment, variation included in antibody techniques, and limited life span of host animal are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying